logo
Plus   Neg
Share
Email

Axel Springer To Withdraw From Stock Exchange - Quick Facts

KKR & Co. L.P. (KKR) has agreed to make a a public delisting offer to the Axel Springer SE (AXELF.PK) shareholders with an offer price amounting to 63 euros in cash per share. Axel Springer SE plans to file a delisting application prior to the expiration of the acceptance period of the offer.

In July 2019, KKR announced its intention to propose a delisting to the other consortium members and to the Executive Board of Axel Springer SE following the successful tender offer. Through the public tender offer as well as additional purchases, KKR has acquired approximately 44.9 percent of Axel Springer's share capital.

Friede Springer and Mathias Döpfner together hold approximately 45.4 percent of Axel Springer's share capital. They will not tender these shares directly or indirectly into the delisting offer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Moderna said Tuesday that it has reached an agreement with the U.S. to initially supply 100 million doses of its experimental vaccine for COVID-19, mRNA-1273. The U.S. government has awarded up to $1.525 billion for the vaccine. Las Vegas, Nevada-based Mr. Wok Foods has recalled about 200,000 pounds of meat and poultry products for misbranding and undeclared allergens, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS said. The recalled products may contain known allergens such as milk, wheat, soy, peanuts, or oysters. They may also contain MSG, sesame products, or sulfites. The U.S. Food and Drug Administration approved the first oral drug to treat patients two months of age and older with spinal muscular atrophy (SMA) that can be taken at home. Roche subsidiary Genentech's Evrysdi (risdiplam) is also the second FDA-approved drug to treat this rare and often fatal genetic disease affecting muscle strength and movement.
Follow RTT